DeepMed Research

Arrowhead Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1989-01-01

Employees: 525

Market Cap: $2.9B

Website: http://www.arrowheadpharma.com

Introduction: Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Clinical Trials

Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy

Phase 1

Recruiting

Conditions: Myotonic Dystrophy 1

Interventions: Drug: ARO-DM1 for Injection
Drug: Placebo

First Posted Date: 2023-11-18

Last Posted Date: 2025-03-26

Lead Sponsor: Arrowhead Pharmaceuticals

Target Recruit Count: 36

Registration Number: NCT06138743

Locations: 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇹🇭
Research Site, Bangkok, Thailand

Study of ARO-DUX4 in Adult Patients With Facioscapulohumeral Muscular Dystrophy Type 1

Phase 1

Recruiting

Conditions: Facio-Scapulo-Humeral Dystrophy

Interventions: Drug: ARO-DUX4 for Injection
Drug: Placebo

First Posted Date: 2023-11-15

Last Posted Date: 2025-03-26

Lead Sponsor: Arrowhead Pharmaceuticals

Target Recruit Count: 60

Registration Number: NCT06131983

Locations: 🇹🇭
Research Site, Bangkok, Thailand

Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS)

Phase 1

Withdrawn

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: ARO-SOD1 Injection

First Posted Date: 2023-07-18

Last Posted Date: 2024-04-17

Lead Sponsor: Arrowhead Pharmaceuticals

Registration Number: NCT05949294

Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis

Phase 1

Recruiting

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: ARO-MMP7 Inhalation Solution
Drug: Placebo

First Posted Date: 2022-09-13

Last Posted Date: 2025-04-04

Lead Sponsor: Arrowhead Pharmaceuticals

Target Recruit Count: 97

Registration Number: NCT05537025

Locations: 🇮🇹
San Giuseppe Hospital, Milano, Italy
🇩🇰
Rigshospitalet- University Hosptial of Copenhagen, Copenhagen, Denmark
🇩🇰
Odense University Hospital, Odense, Denmark

and more 16 locations

Study of ARO-RAGE in Healthy Subjects

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: ARO-RAGE Injection
Drug: Placebo

First Posted Date: 2022-09-09

Last Posted Date: 2024-03-29

Lead Sponsor: Arrowhead Pharmaceuticals

Target Recruit Count: 43

Registration Number: NCT05533294

Locations: 🇳🇿
Research Site, Grafton, Aukland, New Zealand

Study of ARO-APOC3 in Adults With Dyslipidemia

Phase 2

Active, not recruiting

Conditions: Dyslipidemias

Interventions: Drug: ARO-APOC3

First Posted Date: 2022-06-09

Last Posted Date: 2025-01-07

Lead Sponsor: Arrowhead Pharmaceuticals

Target Recruit Count: 418

Registration Number: NCT05413135

Locations: 🇺🇸
Westside Medical Associates of Los Angeles, Beverly Hills, California, United States
🇺🇸
Valley Clinical Trials; Inc., Northridge, California, United States
🇺🇸
Desert Medical Group, Inc., Palm Springs, California, United States

and more 57 locations

Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease

Phase 1

Terminated

Conditions: Chronic Obstructive Pulmonary Disease
Asthma

Interventions: Drug: Placebo
Drug: ARO-MUC5AC

First Posted Date: 2022-03-23

Last Posted Date: 2024-12-13

Lead Sponsor: Arrowhead Pharmaceuticals

Target Recruit Count: 78

Registration Number: NCT05292950

Locations: 🇦🇺
Mater Hospital, South Brisbane, Queensland, Australia
🇦🇺
Institute For Respiratory Health - Perth, Nedlands, Australia
🇰🇷
The Catholic University of Korea Bucheon St. Mary's Hospital, Bucheon, Gyeonggi-do, Korea, Republic of

and more 10 locations

Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: ARO-RAGE
Drug: Placebo

First Posted Date: 2022-03-11

Last Posted Date: 2025-05-18

Lead Sponsor: Arrowhead Pharmaceuticals

Target Recruit Count: 275

Registration Number: NCT05276570

Locations: 🇦🇺
Mater Hospital, South Brisbane, Queensland, Australia
🇦🇺
Institute for Respiratory Health-Perth, Nedlands, Western Australia, Australia
🇰🇷
Jeonbuk National University Hospital, Jeonju, Korea, Republic of

and more 10 locations

Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)

Phase 2

Active, not recruiting

Conditions: Homozygous Familial Hypercholesterolemia

Interventions: Drug: ARO-ANG 3 Injection

First Posted Date: 2022-02-01

Last Posted Date: 2024-05-02

Lead Sponsor: Arrowhead Pharmaceuticals

Target Recruit Count: 18

Registration Number: NCT05217667

Locations: 🇺🇸
Icahn School of Medicine at Mt. Sinai, Mount Sinai, New York, United States
🇺🇸
Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio, United States
🇦🇺
Linear Clinical Research, Nedlands, Western Australia, Australia

and more 4 locations

Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

Phase 3

Active, not recruiting

Conditions: Familial Chylomicronemia

Interventions: Drug: Placebo
Drug: Plozasiran

First Posted Date: 2021-10-22

Last Posted Date: 2025-04-30

Lead Sponsor: Arrowhead Pharmaceuticals

Target Recruit Count: 75

Registration Number: NCT05089084

Locations: 🇵🇱
Instytut Centrum Zdrowia Matki Polki, Łódź, Poland
🇺🇸
Excel Medical Clinical Trials, LLC, Boca Raton, Florida, United States
🇺🇸
Ascension St. Vincent Cardiovascular Research Institute, Indianapolis, Indiana, United States

and more 55 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy